In a patient with chronic pulmonary sarcoidosis who remains symptomatic or steroid‑dependent despite an adequate trial of oral prednisone, how should leflunomide be initiated, dosed, monitored, and what are the contraindications?

Leflunomide in Pulmonary Sarcoidosis

Leflunomide is an effective second-line steroid-sparing agent for chronic pulmonary sarcoidosis, though it is not formally recommended in the 2021 ERS guidelines, which prioritize methotrexate and infliximab based on stronger evidence.

Position in Treatment Algorithm

While the 2021 ERS guidelines do not make a formal recommendation for leflunomide, they acknowledge it as an effective alternative agent alongside azathioprine and mycophenolate mofetil 1. The guidelines specifically recommend:

• First-line: Glucocorticoids (prednisone 20-40 mg daily)
• Second-line: Methotrexate (conditional recommendation, very low quality evidence) 1
• Third-line: Infliximab for refractory disease 1

Leflunomide should be considered when:

• Methotrexate has failed or caused intolerable side effects
• Patient requires steroid-sparing therapy but cannot tolerate methotrexate
• Progressive disease despite adequate glucocorticoid trial

Dosing and Initiation

Loading Dose Considerations

For sarcoidosis patients, AVOID the standard 100 mg × 3 days loading dose 2. The FDA label explicitly states that elimination of the loading dose may decrease adverse events, particularly important for patients:

• Receiving concomitant methotrexate or other immunosuppressives
• Recently on such medications
• At increased risk of hematologic or hepatic toxicity 2

Maintenance Dosing

• Start at 10 mg daily (lower than the RA dose of 20 mg)
• May increase to 20 mg daily if tolerated and needed for disease control
• Do not exceed 20 mg daily - doses of 25 mg/day showed greater incidence of alopecia, weight loss, and liver enzyme elevations 2
• If 20 mg is not tolerated, reduce back to 10 mg daily 2

Monitoring Requirements

Baseline Assessment

Before initiating leflunomide:

• Complete blood count (CBC with differential, platelets, hemoglobin/hematocrit)
• Liver function tests (ALT/SGPT at minimum, also AST and albumin)
• Pregnancy test for women of childbearing potential (absolute contraindication) 2
• Screen for active infections, particularly tuberculosis

Ongoing Monitoring

First 6 months 2:

• CBC with platelets: Monthly
• ALT (SGPT): Monthly
• If on concomitant methotrexate: ALT, AST, and serum albumin monthly (follow ACR methotrexate guidelines)

After 6 months 2:

• CBC with platelets: Every 6-8 weeks
• Liver enzymes: Every 6-8 weeks
• If on concomitant methotrexate: Continue monthly monitoring

Management of Abnormal Labs

Liver enzyme elevations 2:

• ALT 2-3× ULN (confirmed): Reduce dose to 10 mg daily, continue close monitoring
• ALT 2-3× ULN (persistent despite dose reduction): Discontinue leflunomide, initiate cholestyramine washout
• ALT >3× ULN: Immediately discontinue, initiate cholestyramine washout

Bone marrow suppression 2:

• Any evidence of pancytopenia, agranulocytosis, or thrombocytopenia: Stop leflunomide immediately
• Initiate cholestyramine or activated charcoal washout
• Monitor hematologic recovery

Contraindications

Absolute Contraindications 2

• Pregnancy or women of childbearing potential not using reliable contraception (teratogenic risk)
• Severe immunodeficiency
• Severe, uncontrolled infections
• Significant hepatic impairment
• Hepatitis B or C infection
• Bone marrow dysplasia

Relative Contraindications/High-Risk Situations 2

• Concomitant use with methotrexate or other immunosuppressives (requires monthly monitoring)
• Recent discontinuation of immunosuppressive therapy
• Prior history of significant hematologic abnormality
• Pre-existing liver disease

Clinical Efficacy Data

The largest retrospective study of leflunomide in sarcoidosis (n=76) demonstrated 3:

• Pulmonary response: Mean FVC improved by +0.09 L in 6 months after leflunomide (vs. -0.1 L in prior 6 months, p=0.01)
• Extrapulmonary response: 51% good response, 32% partial response
• Steroid-sparing effect: Median prednisone dose reduced from 10 mg to 0 mg at 6 months (p<0.001)
• Tolerability: 34% experienced side effects, 17% discontinued due to adverse events

Critical Safety Considerations

Immunosuppression Risk

Leflunomide increases susceptibility to serious infections including 2:

• Pneumocystis jiroveci pneumonia
• Tuberculosis (including extrapulmonary)
• Aspergillosis
• Sepsis (potentially fatal)

If serious infection develops: Interrupt leflunomide therapy and consider cholestyramine washout.

Drug Elimination Procedure

Due to leflunomide's prolonged half-life (active metabolite persists for weeks to months), rapid elimination may be necessary 2:

Cholestyramine washout:

• 8 grams three times daily for 11 days
• Verify plasma levels <0.02 mg/L with two separate tests 14 days apart
• Use when: severe adverse events, pregnancy, switching to another immunosuppressant, or persistent ALT elevation

Alternative: Activated charcoal 50 grams four times daily for 11 days

Switching from Other Immunosuppressants

When transitioning from methotrexate or other agents to leflunomide 2:

• Monitor for overlapping toxicity (hematologic suppression risk)
• Consider washout period for prior agent
• Maintain monthly hematologic monitoring during transition

Practical Implementation

Common pitfalls to avoid:

1. Using the 100 mg loading dose in sarcoidosis patients (increases toxicity risk)
2. Inadequate monitoring frequency in first 6 months
3. Continuing therapy with persistent ALT 2-3× ULN without dose reduction
4. Failing to counsel women of childbearing potential about teratogenicity
5. Not recognizing need for drug elimination in serious adverse events

Duration of therapy: Like other immunosuppressants in sarcoidosis, treatment duration is typically prolonged. Re-evaluate need for continued therapy every 1-2 years 1. Discontinuation after 6-12 months is associated with >50% relapse rate.